IL6 and hepatocellular carcinoma: For example, higher baseline serum levels of inflammatory markers (CRP, IL‐6, C‐peptide) are associated with an increased risk of developing hepatocellular carcinoma in the general population (Aleksandrova et al., 2014), and the use of anti‐inflammatory drugs is linked to lower risk and better survival in patients with hepatocellular carcinoma (Pang et al., 2017; Sahasrabuddhe et al., 2012; Tao et al., 2018).